bioMérieux and Baxter get together to improve identification and treatment of acute kidney injury

Baxter International Inc. and bioMérieux have recently announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). AKI is a sudden decrease in kidney function over a period of hours to days, often the result of illness, trauma, or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, may lead to death. The most severe stage of AKI requires renal replacement therapy (dialysis) to replace the function of the kidneys. AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals and early diagnosis is critical.